Advisory Board

CV

Philipp von Lattorff (Chairman Advisory Board ViraTherapeutics) started his career at IBM Austria in 1991. Two years later, he joined Boehringer Ingelheim, Vienna, in the area management for Eastern Europe. Other significant stages along his way were management functions in the Baltic region, in Hungary and Italy as well as Regional Business Management Positions for Europe and as CEO for the Central and Eastern European region for CSC pharmaceuticals. In 2011, he joined Boehringer Ingelheim as Head of Emerging Markets before taking over his current role as Country Managing Director of the Boehringer Ingelheim Regional Center Vienna in 2013 where he is responsible for the company’s pharmaceutical business in more than 30 countries in Central and Eastern Europe, Central Asia and Israel.

CV

Personal Details

Name:	Derek O’Leary
Date of birth:	31.01.1970
Place of birth:	Enniscorthy, Co. Wexford, Ireland
Nationality:	Irish
Professional Experience
06/2019 – now	Head of Finance & Administration RCV
02/2013 – 05/2019	CFO/Head of Finance Division Boehringer Ingelheim Japan Inc.
10/2007 – 01/2013	Head of Finance & Administration BI Espana
11/2002 - 09/2007	Finance Director BI Ilac Ticaret (BI Turkey)
04/2001 – 10/2002	Country Controller, Corp. Dept. Subsidiaries Controlling, BI GmbH
07/1997 – 03/2001	Regional Controller, BI Pharma Orient, Egypt
10/1994 – 06/2007	Project Controller, Methods & Procedures, Corp. Division Controlling, BI GmbH
01/1992 – 09/1994	Financial Analyst, Alfa Metalcraft Corporation, Bingen, Germany
07/1991 – 12/1991	Credit Controller, Triton Finance, Rank Xerox Financial Services, Slough, UK
Education:
1988 - 1991	BA in Accounting & Finance, Dublin City University, Ireland
1984 – 1988	FCJ Bunclody, Co. Wexford, Ireland completion of leaving certificate (abitur equivalent)

Language Skills

English – native
Irish – native
German – fluent
Spanish – fluent
French – conversational
Turkish - conversational
Japanese – N3 proficient, intermediate
Italian - basic

Additional Skills:

Treasurer of Ireland/Japan Chamber of Commerce, Experience in organizing charitable events

Additional courses:

Global Strategic Leadership Program, Situational Leadership, Management Centre Europe, Center for Creative Leadership, plus various others

Interests:

Foreign languages and culture, travel, listening to music & podcasts, sports (gym, football, tennis), spending time with family

CV

Paul Adam B.Sc. (Hons) Ph.D. was born in Dumfriesshire, Scotland and was educated at Dundee University (B.Sc with Honors in Biochemistry) and Cambridge University (Ph.D. in Biochemistry). His subsequent academic career included post-doctoral research positions in at the University of Virginia and Cambridge University where he became a Research Fellow of Wolfson College. In 2000 Dr. Adam began his career in the biopharmaceutical industry at Oxford Glycosciences and then Celltech where he was responsible for oncology biologics research and therapeutic antibody programs. Since joining Boehringer Ingelheim in 2005 as Head of Antibody Drug Discovery Dr. Adam has held several roles of increasing responsibility and has led the discovery and development of numerous biological drugs that have advanced into clinical trials for the treatment of cancer. Dr. Adam is currently Global Cancer Immunology & Immune Modulation Scientific Coordinator at Boehringer Ingelheim.

CV

Besides serving as a member of the Supervisory Board of ViraTherapeutics, Dr. Ralf Schumacher is currently the Head of Development Biologicals in the Development Unit within Boehringer Ingelheim. In this capacity, he is accountable for all non-clinical development activities which are required to bring a biological clinical candidates into clinics and subsequently through clinical development up to launch. Corresponding disciplines comprise all CMC functions (from cell line development, USP, DSP, Analytics, Formulation, Primary Packaging up to Combination Product development), DMPK (bioanalytical method development, PK & ADA studies in animals and humans), and non-clinical drug safety. Soon, a unit for clinical trial supplies will be added. The units are located in Germany and the US. Boehringer Ingelheim is committed to innovation and strives for development of first-in-class Biologicals with breakthrough potential. The Biologicals' portfolio includes monoclonal antibodies, engineered multi-functional NBEs, and new (ATMP) modalities.